Aktieanalyser från populära analyshus

Senaste aktieanalyserna

Xbrane Biopharma: Biogen deal terminated (BIIB801) - Redeye

Analys | Redeye

•

01 Aug 2024 11:54

Xbrane Biopharma: Biogen deal terminated (BIIB801) - Redeye

Føroya Banki: Solid Q2 and positive outcome of the Danish FSA’s investigation of the Faroese and Greenlandic property market - Nordea

Q2 2024 profit before loan losses came in at DKK 63m, DKK 7m (10%) below our estimate.

Foroya Banki

Føroya Banki: Solid Q2 and positive outcome of the Danish FSA’s investigation of the Faroese and Greenlandic property market - Nordea

Analys | ABG Sundal Collier

•

01 Aug 2024 07:41

Tethys Oil: Moving ahead on block 56 - ABG

Tethys Oil

Analys | ABG Sundal Collier

•

01 Aug 2024 07:39

SinterCast: EEs announced, est. sales +11%, 38% margin - ABG

Q2e: 4.0m EEs, 58k SCs pre-announced, expect SEK 13m EBIT Cut sales by ~4%, EBIT by ~6% on lower EE ...

Ortoma: DePuy agreement yielding results - Redeye

Sleep Cycle: Stable delivery with an optimistic outlook - Redeye

Redeye updates its estimates on Sleep Cycle following its Q2 2024 quarterly report, which matched ou...

Sleep Cycle

Analys | ABG Sundal Collier

•

31 Jul 2024 14:47

Freemelt: First eMELT delivery in Q2e - ABG

Freemelt

Analys | Analyst Group

•

30 Jul 2024 12:56

Analyst Group kommenterar Obducats Q2-rapport

Obducat publicerade den 26 juli 2024 bolagets delårsrapport för det andra kvartalet 2024, vilken vis...

Suominen: Earnings recovery should gather pace - Evli

Etteplan: Expecting continued improvement - Evli

Etteplan publishes its Q2/24 figures on 8th of August.

EG7: Accelerating cost cuts in service business - Redeye

Føroya Banki: 2024E net profit at the top of guidance range - Nordea

Føroya Banki reports its Q2 2024 results on 1 August 2024.

Scanfil: Order intake has not improved as expected - Nordea

Scanfil

Analys | Analysguiden

•

29 Jul 2024 13:52

Coor: Vinsten på återhämtning - Analysguiden

Servicebolaget Coor rapporterade ett andra kvartal som kom in något över Analysguidens prognos.

Coor Service Management

Analys | Redeye

•

29 Jul 2024 10:43

Xspray Pharma: Dasynoc CRL – Initial Comments - Redeye

Xspray Pharma

Analys | Analysguiden

•

29 Jul 2024 09:58

Addlife: Organisk tillväxt imponerar - Analysguiden

Addlife har en solid position inom en bransch med stabil och ökande efterfrågan.

Safeture: Profitability set to be reached in the second half of 2024 - Redeye

Physitrack: Preview Q2 2024e - Redeye

Redeye anticipates a muted Q2 2024 in terms of quarter-on-quarter growth, though stable ARR growth i...

OXE Marine: Key priority to restore finances - Redeye

Incap: Ordinary result was not enough for the markets - Nordea

Net sales and clean EBIT were in line with consensus but the share price declined by 7.

Impact Coatings: Another IC2000 order - Redeye

BioArctic: Negativ rekommendation från EUs läkemedelskommitté (CHMP) - Redeye

Redeye ger en kort kommentar om det negativa utlåtandet från CHMP.

EG7: Preliminary Q2-results below expectations - Redeye

Enad Global 7

Analys | ABG Sundal Collier

•

29 Jul 2024 07:41

PION Group: Not the recovery we were looking for - ABG

Sales down 20% y-o-y in Q2 More restructuring in the quarter Overall market has likely trouged Q2: ...

PION Group

Analys | ABG Sundal Collier

•

26 Jul 2024 15:17

Studsvik: Strong sales growth in Q2 - ABG

Studsvik

Analys | Analyst Group

•

26 Jul 2024 10:45

Analyst Group kommenterar Kinda Braves förlagsavtal med en europeisk spelförläggare

Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) meddelade den 25 juli år 2024 a...

Alzinova: Appoints new acting CEO - Redeye

Incap: Q2 in line with consensus, FY guidance unchanged - Nordea

Net sales and adjusted EBIT were close to market consensus (LSEG) in Q2.

Vaisala: Strong Q2 makes up for the slow start - Evli

OXE Marine Q2 2024: Initial take - Redeye

Redeye was hoping for higher sales in the second quarter.

OXE Marine

Föregående Nästa